Author, year | Country | Time frame | Search strategy/ Database | RCTs (n) | RCTs (n) included in our overview. | P | I | C | O | Funding | Conflicts of interest. | AMSTAR assessment |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Iacovelli 2014 [23] | USA | From January 2004 to February 2014 | Cochrane Central Register of Controlled Trials, MEDLINE, PubMed. | 5 | 5 | Gastric cancer | CT, Biological, or targeted therapy | BSC / Supportive care | Functional status, OS | No | None | CRITICALLY LOW |
TerVeer 2016 [24] | Netherlands | Up to January 2016 | Cochrane Central Register of Controlled Trials, EMBASE, MEDLINE. | 28 | 8 | Esophageal, gastric, and GEJ cancer | CT, Biological, or targeted therapy | BSC / Placebo | OS, PFS, Toxicity | No | Yes | CRITICALLY LOW |
Wang 2016 [25] | China | Up to December 31, 2015 | Cochrane Library, EMBASE, PubMed | 10 | 3 | Gastric cancer | Biological or targeted therapy | Placebo | OS | Public | None | LOW |
Chan a 2017 [26] | Australia | Up to December 2014 | Cochrane Central Register of Controlled Trials, EMBASE, PubMed. | 15 | 4 | Gastric and GEJ cancer | Biological or targeted therapy | Placebo | OS, PFS, Toxicity, QoL | No | Yes | CRITICALLY LOW |
Chan b 2017 [27] | China | Up to 2016 | CINAHL, Cochrane Central Register of Controlled Trials, EMBASE, MEDLINE | 5 | 5 | Gastric and GEJ cancer | CT, Biological, or targeted therapy | BSC / Placebo | OS, PFS, Toxicity | No | None | HIGH |
Harvey 2017 [28] | UK | Between 1990 and 2015 | PubMed, Scopus. | 5 | 5 | Gastric and GEJ cancer | CT | BSC | OS | NR | NR | CRITICALLY LOW |
Janmaat 2017 [15] | Netherlands | Up to 13 May 2015 | Cochrane Central Register of Controlled Trials, Clinicaltrials.gov, EMBASE, Google Scholar, MEDLINE, PubMed, Web of Science, WHO International Clinical Trials Registry Platform (ICTRP) | 41 | 5 | Esophageal and GEJ cancer | CT, Biological, or targeted therapy | BSC / Placebo / Non-specified | OS | Public | None | HIGH |
Wagner 2017 [29] | Switzerland | Up to June 2016 | Cochrane Central Register of Controlled Trials, MEDLINE, Hand searched reference lists from studies, abstracts, conference. | 64 | 3 | Gastric and GEJ cancer | CT | BSC | OS | Public | Yes | HIGH |
Wang 2017 [30] | China | Up to December 2015 | Embase, Medline, the Cochrane Central Register of Controlled Trials, Cochrane Database of Systematic Reviews, EMBASE, MEDLINE | 9 | 2 | Gastric cancer | Biological or targeted therapy | Placebo | Toxicity | NR | None | MODERATE |
Xie 2017 [31] | China | Between January 1st, 2000 and October 1st, 2016 | Cochrane Library and Scopus, EMBASE, | 23 | 2 | Gastric and GEJ cancer | CT, Biological, or targeted therapy | Placebo | OS | NR | None | CRITICALLY LOW |
Zhu 2017 [32] | Canada | Up to June 2014 | American Society of Clinical Oncology abstracts, Cochrane Central Register of Controlled Trials, EMBASE, MEDLINE. | 8 | 5 | Gastric and GEJ cancer | CT, Biological, or targeted therapy | BSC / Placebo | OS | Private | Yes | CRITICALLY LOW |
Liu 2018 [33] | China | Up to March 15, 2017 | Cochrane Central Register of Controlled Trials, Clinicaltrials.gov, EMBASE, EU Clinical Trials Register, Japan Pharmaceutical Information Center, PubMed. | 8 | 4 | Gastric and GEJ cancer | Biological or targeted therapy | Placebo | OS, PFS, Toxicity | Public / Private | None | LOW |
Zhao 2018 [34] | China | Between 2002 and 2017 | Cochrane Library, EMBASE, PubMed. | 16 | 6 | Esophageal, gastric and GEJ | Biological or targeted therapy | Placebo | OS, PFS, Toxicity | Public | None | CRITICALLY LOW |
Chen 2019 [35] | China | Up to September 2018 | PubMed | 9 | 2 | Gastric and GEJ cancer | Immunotherapy | BSC / Placebo | OS, PFS, Toxicity | Public | None | CRITICALLY LOW |
van Kleef 2019 [36] | Netherlands | Up to April 2018 | Cochrane Central Register of Controlled Trials, EMBASE, MEDLINE. | 43 | 8 | Esophageal, gastric and GEJ | CT, Biological, or targeted therapy | BSC / Placebo | QoL | Public | Yes | CRITICALLY LOW |
Wallis 2019 [37] | Canada | Up to October 2, 2018 | EMBASE, MEDLINE, PubMed, Scopus. | 23 | 1 | Gastric and GEJ cancer | Immunotherapy | Placebo | OS | Private | Yes | CRITICALLY LOW |